Application Note: Development of a Red Fluorescent Labeled Agent for Assessing HER2 Expression
22 July 2013

Despite the clinical importance of HER2 expression in breast, ovarian, and stomach cancer, until now there have been no established research agents available for non-invasive optical imaging in pre-clinical models of cancer. The ability to image HER2 can provide an important tool for cancer detection and quantification as well as for the assessment of target coverage for HER2-specific therapies. In this application note read about a red fluorescent imaging agent, specific for tumor HER2, that is conjugated to Trastuzumab. This application note provides the in vitro and in vivo datasets that characterize this red fluorescent imaging agent and provides detailed protocols and examples that illustrate its utility in pre-clinical imaging.